Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aztreonam lysine (Cayston) versus placebo in adults with bronchiectasis
2018-001590-24Phase 2Suspended
- Sponsor
- University of Dundee
- Start
- Jan 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of aztreonam in bronchiectasis (3 arms), sponsored by University of Dundee. Primary endpoint: Safety and tolerability (adverse events, serious adverse events, treatment withdrawals). Started Jan 2019; status: suspended.
02
Drugs
aztreonam
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2018-001590-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001590-24.